2026-04-13T00:04:22Zhttps://recercat.cat/oai/request

oai:recercat.cat:2445/2229822025-12-05T01:01:45Zcom_2072_1057col_2072_478916col_2072_478917

00925njm 22002777a 4500 dc Bruna, Jordi author Miró, Júlia author Velasco, Roser author 2025-09-05T09:56:55Z 2025-09-05T09:56:55Z 2013-05-01 2025-09-04T09:09:26Z Glioblastoma-related epilepsy requires paying careful attention to a combination of factors with an integrated approach. Major interrelated issues must be considered in the seizure care of glioblastoma patients. Seizure control frequently requires the administration of antiepileptic drugs simultaneously with other treatments, including surgery, radiotherapy and chemotherapy, with complete seizure relief often being difficult to achieve. The pharmacological interactions between antiepileptic drugs and antineoplastic agents can modify the activity of both treatments, compromising their efficacy and increasing the probability of developing adverse events related to both therapies. This review summarizes the new pathophysiological pathways involved in the epileptogenesis of glioblastoma-related seizures and the interactions between antiepileptic drugs and oncological treatment, paying special attention to its impact on survival and the current evidence of the antiepileptic treatment efficacy, including the potential usefulness of new third-generation compounds. Epilèpsia Glioma Terapèutica Epilepsy Gliomas Therapeutics Epilepsy in glioblastoma patients: basic mechanisms and current problems in treatment